Skip to main content

Table 1 Profile of NK cells derived from healthy donors and bladder cancer patients

From: Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells

 

Healthy donors

Bladder cancer patients

51Cr-release assay

HT-1376

80.12 ± 4.14 %

38.67 ± 8.88 %***

HT-1376 spheres

75.44 ± 6.53 %

11.74 ± 3.12 %***

UM-UC3

73.69 ± 5.40 %

41.38 ± 10.71 %**

UM-UC3 spheres

67.52 ± 7.61 %

18.19 ± 4.17 %***

NCRs

NKp30

54.68 ± 4.98 %

33.55 ± 5.09 %*

NKp44

26.35 ± 9.18 %

0.52 ± 0.20 %***

NKp46

42.93 ± 3.70 %

49.09 ± 6.09 %

NKp80

98.34 ± 0.32 %

91.36 ± 2.20 %**

 CD62L

33.40 ± 1.44 %

24.30 ± 2.57 %*

 CD57

31.08 ± 2.54 %

20.86 ± 2.14 %**

Cytokines

TNF-α

0.36 ± 0.13 %

0.23 ± 0.08 %

IFN-γ

0.23 ± 0.06 %

0.08 ± 0.03 %

TGF-β

0.14 ± 0.02 %

0.32 ± 0.15 %

IL-4

0.007 ± 0.003 %

0.42 ± 0.24 %

IL-10

0.81 ± 0.19 %

3.36 ± 1.62 %

  1. 51Cr chromium-51, NCRs natural cytotoxic receptors
  2. *P < 0.05; **P < 0.01; ***P < 0.001 healthy donors (n = 8) vs. bladder cancer patients (n = 10)